Synthekine Inc is a biotechnology company based in Menlo Park, CA, dedicated to discovering, developing, and commercializing the next generation of selective cytokine therapeutics. With a focus on cancer and inflammatory disease treatment, they are leveraging their expertise in protein engineering to overcome the limitations of current cytokine therapeutics and cell therapies.
Through their three distinct protein engineering platforms, including cytokine partial agonist, orthogonal cytokine cell therapy, and surrogate cytokine technologies, Synthekine is revolutionizing the treatment paradigm by creating potentially paradigm-changing medicines. Their broad and deep pipeline of selective immunotherapies targets a wide range of important disease indications, aiming to transform the way these conditions are managed.
Generated from the website